Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130728 | 0.87 | KDM4E (0.54) | MTNR1AMTNR1BKDM4ENPC1TSHR | |
| SCHEMBL6596508 | 0.82 | MTNR1A (0.42) | MTNR1AMTNR1BKDM4ENPC1TSHR | |
| SCHEMBL6230318 | 0.80 | MTNR1A (0.46) | MTNR1AMTNR1BKDM4ENPC1TSHR | |
| SCHEMBL6984243 | 0.76 | MTNR1A (0.43) | MTNR1AMTNR1BKDM4ENPC1TSHR | |
| SCHEMBL14034583 | 0.74 | KDM4E (0.56) | KDM4EPOLBLMNAMAPTMAPK1 | |
| SCHEMBL8555827 | 0.74 | MTNR1A (0.56) | MTNR1AMTNR1BKDM4ENPC1RAB9A | |
| SCHEMBL3050845 | 0.73 | HTT (0.46) | KDM4ENPC1TSHRPOLBHTT | |
| SCHEMBL4643044 | 0.73 | CA2 (0.45) | NPC1RAB9AHTTLMNAMAPT | |
| SCHEMBL25030256 | 0.72 | MTNR1A (0.64) | MTNR1AMTNR1BACHE | |
| SCHEMBL25987515 | 0.72 | HTR1D (0.58) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1084711-B1 | REMEDIES FOR THE TREATMENT OF ITCHING CONTAINING PGD2 ANTAGONISTS | SHIONOGI & CO (JP) | 2005-05-11 | — | — | EP | disclosed |
| EP-1528060-A1 | Process for preparing 5-hydroxy[b]thiophene-3-carboxylic acid derivatives | SHIONOGI & CO., LTD. (JP) | 2005-05-04 | — | — | EP | disclosed |
| EP-1016660-B1 | COMPOUNDS HAVING 2.2.1]BICYCLO SKELETON | SHIONOGI & CO (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-20030027854-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | SHIONOGI & CO., LTD. | 2003-02-06 | — | — | US | disclosed |
| US-6506789-B2 | For prophylaxis and therapy of itching derived from contact dermatitis, allergic conjunctivitis, urticaria, atopic dermatitis | SHIONOGI & CO., LTD. (JP) | 2003-01-14 | — | — | US | disclosed |
| US-6495702-B2 | SPECIFIC PGD2 ANTAGONISTS; STARTING MATERIALS FOR PRODUCING DRUGS | SHIONOGI & CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-0944614-B1 | BENZOTHIOPHENECARBOXAMIDE DERIVATIVES AND PGD2 ANTAGONISTS COMPRISING THEM | SHIONOGI & CO (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-20020058693-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | ARIMURA AKINORI (JP) | 2002-05-16 | — | — | US | disclosed |
| US-20020026061-A1 | Process for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives | HONMA TSUNETOSHI (JP) | 2002-02-28 | — | — | US | disclosed |
| US-6346628-B1 | REACTING 4-MERCAPTOPHENOL WITH A PROPARYGL GOUP AND PROTECTION OF HYDROXYL GROUP, OXIDIZING THE PRODUCT, AND THERMAL REARRANGEMENT TO CYCLIZE, FOLLOWED BY FURTHER OXIDATION | SHIONOGI & CO., LTD. (JP) | 2002-02-12 | — | — | US | disclosed |
| US-20020016476-A1 | PROCESS FOR PREPARING 5-HYDROXYBENZO [B] THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES | HONMA TSUNETOSHI (JP) | 2002-02-07 | — | — | US | disclosed |
| US-6320060-B1 | INTRODUCING PROPARGYL GROUP INTO 4-MERCAPTOPHENOL, PROTECTING HYDROXYL GROUP, OXIDIZING COMPOUND, SUBJECTING TO THERMAL REARRANGEMENT REACTION, SUBJECTING TO STEPWISE OXIDATION OF HYDROXYMETHYL GROUP AND OPTIONALLY DEPROTECTION | SHIONOGI & CO., LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| US-6225336-B1 | FOR THERAPY OF SYSTEMIC MASTOCYTOSIS AND DISORDER OF SYSTEMIC MAST CELL ACTIVATION AS WELL AS TRACHEAL CONTRACTION, ASTHMA, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, URTICARIA, ISCHEMIC REPERFUSION INJURY, AND INFLAMMATION | SHIONOGI & CO., LTD. (JP) | 2001-05-01 | — | — | US | disclosed |
| EP-1084711-A1 | REMEDIES FOR ITCHING CONTAINING PGD 2? ANTAGONISTS | SHIONOGI & CO., LTD. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-1069122-A1 | PROCESS FOR PRODUCING 5-HYDROXYBENZO b]THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2001-01-17 | — | — | EP | disclosed |
| EP-1016660-A1 | COMPOUNDS HAVING 2.2.1]BICYCLO SKELETON | SHIONOGI & CO., LTD. (JP) | 2000-07-05 | — | — | EP | disclosed |
| US-6083974-A | BENZOTHIOPHENECARBOXAMIDE CONTAINING NORPINANE RING IS USEFUL FOR PREVENTING NASAL BLOCKAGE | SHIONOGI & CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| EP-0944614-A1 | BENZOTHIOPHENECARBOXAMIDE DERIVATIVES AND PGD2 ANTAGONISTS COMPRISING THEM | SHIONOGI & CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025919-A1 | BENZOTHIOPHENECARBOXAMIDE DERIVATIVES AND PGD2 ANTAGONISTS COMPRISING THEM | SHIONOGI & CO., LTD. (JP) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016476-A1 | PROCESS FOR PREPARING 5-HYDROXYBENZO [B] THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES | HPD, PTGDR2, PTGS2 | MTNR1A 1041/4885MTNR1B 270/4885KDM4E 1993/4885 |
| US-20020026061-A1 | Process for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives | HPD, PTGDR2, PTGS2 | MTNR1A 1041/4885MTNR1B 270/4885KDM4E 1993/4885 |
| US-20020058693-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | HRH2, PTGER2, PTGDR2 | MTNR1A 80/4885MTNR1B 79/4885KDM4E 4756/4885 |
| US-20030027854-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | HRH2, PTGER2, PTGDR2 | MTNR1A 80/4885MTNR1B 79/4885KDM4E 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.